



Bicuspid aortic valves (BAV) Registry (RE-BAV): Clinical and echocardiographic characteristics of patients with BAV according to novel classification of bicuspid aortic valves

Authors: Edyta Płońska-Gościniak, Lidia Tomkiewicz-Pająk, Monika Komar, Tomasz Kukulski, Wojciech Kosmala, Jarosław D Kasprzak, Katarzyna Mizia-Stec, Tomasz Hryniewiecki, Dorota Kustrzycka-Kratochwil, Tomasz Niklewski, Ludmiła Daniłowicz-Szymanowicz, Danuta Sorysz, Wojciech Braksator, Ewa Pilchowska-Paszkiel, Andrzej Gackowski, Zbigniew Gąsior, Andrzej Zych, Ilona Kowalik, Piotr Gościniak, Małgorzata Knapp, Marta Garbowska, Agnieszka Wojtkowska, Rafał Dankowski, Jolanta Gołba, Magda Lipczyńska, Andrzej Minczykowski, Alicja Dąbrowska-Kugacka

Article type: Original article

Received: November 15, 2024

Accepted: May 14, 2025

Early publication date: May 18, 2025

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

Bicuspid aortic valves (BAV) Registry (RE-BAV): Clinical and echocardiographic characteristics of patients with BAV according to novel classification of bicuspid aortic valves

Short title: Bicuspid aortic valves (BAV) Registry (RE-BAV)

Edyta Płońska-Gościniak¹, Lidia Tomkiewicz-Pająk^{2,3,4}, Monika Komar^{3,4}, Tomasz Kukulski⁵, Wojciech Kosmala⁶, Jarosław D Kasprzak⁷, Katarzyna Mizia-Stec⁸, Tomasz Hryniewiecki⁹, Dorota Kustrzycka-Kratochwil¹⁰, Tomasz Niklewski¹¹, Ludmiła Daniłowicz-Szymanowicz¹², Danuta Sorysz¹³, Wojciech Braksator¹⁴, Ewa Pilchowska-Paszkiel¹⁵, Andrzej Gackowski¹⁶, Zbigniew Gąsior¹⁷, Andrzej Zych¹⁸, Ilona Kowalik¹⁹, Piotr Gościniak²⁰, Małgorzata Knapp²¹, Marta Garbowska²², Agnieszka Wojtkowska²³, Rafał Dankowski²⁴, Jolanta Gołba¹⁷, Magda Lipczyńska¹⁹, Andrzej Minczykowski²⁵, Alicja Dąbrowska-Kugacka¹²

¹Department of Cardiology, Pomeranian Medical University, Szczecin, Poland

²Center of Adult Congenital Heart Diseases, Kraków, Poland

³Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland

⁴St. John Paul II Hospital, Kraków, Poland

⁵Clinical Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Specialistic Hospital in Zabrze, Poland

⁶Institute of Heart Diseases, Wrocław Medical University, Wrocław, Poland

⁷1st Department and Chair of Cardiology, Medical University of Lodz, Łódź, Poland

⁸1st Department of Cardiology, I Chair of Cardiology, Medical University of Silesia, Katowice, Poland

⁹Department of Valvular Heart Disease, National Institute of Cardiology, Warszawa, Poland

¹⁰Department of Cardiac Imaging, Center for Heart Diseases, 4th Military Clinical Hospital, Wrocław, Poland

¹¹Department of Cardiac Surgery and Transplantology Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze, Poland

¹²Department of Cardiology and Electrotherapy, Faculty of Medicine, Medical University of Gdansk, Poland

¹³2nd Department of Cardiology, Jagiellonian University Medical College, Kraków, Poland

¹⁴Department of Sports Cardiology and Noninvasive Cardiovascular Imaging, Warsaw Medical University, Warszawa, Poland

¹⁵Department of Cardiology, Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland

¹⁶Department of Coronary Disease and Heart Failure, Noninvasive Cardiovascular Laboratory, Jagiellonian University Medical College, John Paul II Hospital, Kraków, Poland

¹⁷Department of Cardiology, Medical University of Silesia, Katowice, Poland

¹⁸Department of Cardiac Surgery, 2nd University Hospital, Szczecin, Poland

¹⁹National Institute of Cardiology, Warsaw, Poland

²⁰Laboratory of Non-Invasive Heart Diagnostics and Cardio-Oncology and Department of Endocrinology, Pomeranian Medical University, Szczecin, Poland

²¹Department of Cardiology, Medical University of Białystok, Białystok, Poland

²²Department of Cardiac Surgery, Medical University of Białystok, Białystok, Poland

²³Department of Cardiology, Medical University, Lublin, Poland

²⁴2nd Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland

²⁵Department of Cardiology — Intensive Therapy, Poznan University of Medical Sciences, Poznań, Poland

Correspondence to:

Prof. Alicja Dąbrowska-Kugacka, MD, PhD,
Department of Cardiology and Electrotherapy,
Faculty of Medicine,
Medical University of Gdansk,
Smoluchowskiego 17, 80–214 Gdańsk,
phone +48 58 584 47 60,
e-mail: alicja.dabrowska-kugacka@gumed.edu.pl

WHAT'S NEW?

The publication presents the results of the first Polish Registry of Bicuspid Aortic Valves (RE-BAV) in adults, conducted between 2021 and 2023 across 23 tertiary centers using the latest BAV classification. The registry included 814 patients, providing updated insights into BAV phenotypes in the Polish population. Clinical and echocardiographic data were analyzed, with phenotypes and aortopathy adjudicated using the new classification. The most common phenotype was typical valvulo-aortopathy with valve dysfunction and/or aortic dilatation without major associated diseases. The occurrence of the three BAV phenotypes differs from

previous publications, including a higher prevalence of the partial-fusion BAV type. The fusion type of BAV, particularly right-left cusps fusion, was the most frequent phenotype, while the partial-fusion type also showed a notable presence. Clinical characteristics and comparison of the three BAV phenotypes is provided. The most prevalent aortic malformation was extended aortic dilatation, involving the root and ascending aorta, which differs from previous studies.

ABSTRACT

Background: Bicuspid aortic valve (BAV) is a common congenital heart defect linked to abnormal valve structure and aortic dilatation.

Aims: To present BAV types and valvulo-aortopathy in the Polish population using the latest 2021 classification.

Methods: RE-BAV is a registry of adult ambulatory and hospitalized patients with BAV evaluated in echocardiographic laboratories at 23 tertiary centers in Poland (2021–2023).

Results: The study included 814 patients — 72.7% male, average age — mean (SD) 50 (17.4). Common symptoms included dyspnea (54.1%) and chest pain (17.5%). Hypertension (54%) was the most frequent comorbidity. Left ventricular ejection fraction was normal (median 60%, interquartile range: 55–65), but global longitudinal strain was mildly reduced — mean (SD) –16.8% (3.7). Moderate/severe aortic stenosis was found in 34.2% and regurgitation in 44.1% ($P < 0.001$).

The most common phenotype was typical valvulo-aortopathy (69.9%), followed by uncomplicated BAV (19.3%) and complex valvulo-aortopathy (10.8%). Among 640 patients with specified subtypes, fusion was the most frequent BAV type (79.4%), followed by 2-sinus (15.8%) and partial-fusion (4.8%) ($P < 0.001$ for all comparisons). Patients with the 2-sinus type were the youngest and had the least comorbidities, contrary to the partial-fusion group. Right-left cusp fusion was the most common subtype (80.4% of fusion BAV). Within the 2-sinus type the latero-lateral and antero-posterior phenotypes had similar prevalence. Aortic dilatation occurred in 63.6%, with extended aortic dilatation being most prevalent (26.3%).

Conclusions. The RE-BAV registry provides updated insights into BAV phenotypes and aortopathy in the Polish population, reflecting the latest classification advancements.

Key words: aortopathy, bicuspid aortic valve, valve phenotypes, valvulopathy

INTRODUCTION

The prevalence of bicuspid aortic valve (BAV) in the general population is estimated at 1%–2%, making it the most common adult congenital heart defect [1]. In patients with BAV, in addition to changes in the structure and function of the valve itself (i.e. stenosis or regurgitation), there is often a dilatation of the proximal part of the aorta (root and ascending aorta), known as BAV-related aortopathy. It is a common and heterogenous clinical problem most often recognized during standard echocardiographic examination. This publication presents the results of the first Polish Registry of Bicuspid Aortic Valves (RE-BAV) of the adult population and reports BAV morphology, according to the new latest classification [2].

MATERIAL AND METHODS

The registry was conducted in 23 Polish tertiary cardiological centers, mainly university based, with the participation of echocardiography experts who held the Echocardiography Association Certificates of the Polish Cardiac Society. The registry included consecutive inpatients and outpatients presenting to the echocardiographic laboratories in each of the 23 participating centers between 2021 and 2023. Patients with acute coronary syndrome, hemodynamic instability, or recent valvular heart surgery were excluded. Data on comorbidities, including coronary artery disease, history of myocardial infarction, stroke, clinically significant arrhythmias, atrial fibrillation, arterial hypertension, dyslipidemia, nicotine addiction, diabetes, and malignancy, were recorded. Active neoplastic disease was defined as any malignancy diagnosed in the past 6 months, currently undergoing treatment, or showing recurrence or progression. All subjects underwent medical history, clinical examination, and initial transthoracic echocardiography. If needed, transesophageal echocardiography, cardiac computed tomography, or electrocardiography-gated computed tomography angiography was performed when specific aortic segments could not be visualized or exceeded 45 mm. Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measured when available. According to the decision of Pomeranian Medical University ethical committee no additional formal consent for this study was required. The registry was carried out under the patronage of the Valvular Heart Association of the Polish Cardiac Society.

Echocardiographic examination

Baseline clinical evaluation included M-mode, 2-dimensional (2D) echocardiography, and color Doppler, performed by experienced echocardiographers equipped with state-of-the-art technology following current guidelines [3]. Ventricular volume and ejection fraction were calculated using the 2-plane Simpson method, with 3-dimensional echocardiography used when

available. Regional wall motion abnormalities were noted. Bicuspid aortic valve disease was confirmed in the short axis view at the level of the aortic leaflets (Figure 1) [2]. Evaluation of aortic valve disease with regard to stenosis or regurgitation and 2D measurements of the aorta at various levels were performed according to the latest guidelines (Figure 2) [4, 5]. Additionally mitral and tricuspid valve defects were noted.

Clinical classification of bicuspid aortic valve disease

The BAV disease was categorized into 3 clinical subgroups: (i) **complex valvulo-aortopathy** characterized by concomitant or associated disorders (i.e., Turner syndrome, Loeys–Dietz syndrome, Shone complex, severe aortic coarctation, concomitant non-dilated cardiomyopathy) and/or by early/accelerated valve dysfunction and/or aortopathy; (ii) **typical valvulo-aortopathy** with progressive BAV dysfunction and/or aortic dilatation without other major associated disorders and (iii) **uncomplicated BAV** with mild or non-progressing valvulo-aortopathy without clinical manifestation [2].

Three BAV phenotypes were distinguished: (1) the fused BAV, (2) the 2-sinus BAV and (3) the partial-fusion BAV (Figure 1). **1. The fused BAV** was characterized by 2 of the 3 cusps appearing fused or joined within 3 distinguishable aortic sinuses, resulting in 2 functional cusps. Within the fused type 3 specific BAV phenotypes were differentiated: right–left cusp fusion, right–noncoronary cusp fusion and left–noncoronary cusp fusion. **2. The 2-sinus BAV** type was defined by the presence of 2 cusps of approximately equal size and shape, with each cusp occupying 180° of the annular circumference, and only 2 aortic sinuses, resulting in a 2-sinus/2-cusp valve. Two specific phenotypes of the 2-sinus BAV category were distinguished: latero-lateral (side-to-side) or antero-posterior (front and back) based on the short-axis base-of-the-heart plane. **3. The partial-fusion BAV** was recognized when a typical tricuspid aortic valve with 3 sinuses and 3 symmetrical cusps with a systolic triangular opening and commissural angles of 120 was present, yet at the base of one of the commissures <50% cusp fusion forming a small ‘mini-raphe’ was noted.

Definition of aortic dilatation and bicuspid aortic valve aortopathy

Three forms of aortic dilatation BAV were distinguished according to the latest the American Heart Association/American College of Cardiology 2022 comprehensive guideline for the diagnosis and management of aortic diseases [6]: (i) the ascending phenotype with dilatation preferentially located at the tubular ascending tract beyond the sino-tubular junction, (ii) the root phenotype with dilatation preferentially located at the root (sinuses of Valsalva) and (iii)

the extended phenotype with dilatation of the root, the ascending aorta and the arch (Figure 2). Reference normal values were adopted depending on gender with the cut-off values for aortic root 40 mm and 34 mm, ascending aorta 40 mm and 36 mm, and aortic arch 34 mm and 31mm for men and women respectively [5, 7].

Statistical analysis

Data analysis was performed using SAS version 9.4 (SAS Institute, Cary, NC, US). The normal distribution of all continuous variables was examined using the Kolmogorow–Smirnov test. Numerical variables with normal distribution are presented as mean with standard deviation, and skewed are expressed as median (interquartile range [IQR]). Categorical variables are reported as frequency and percentage and compared using the χ^2 Test for Equal Proportions or McNemar’s Test. The proportion of categorical variables with the number of categories >2 was verified by general association of the Cochran–Mantel–Haenszel test. The differences between numerical variables were assessed by one-way ANOVA, with Tukey’s post-hoc test for pairwise two-sided multiple comparison (normally distributed data) or, in the case of skewed distribution, with Kruskal–Wallis ANOVA with pairwise two-sided multiple comparison by DSFC method (Dwass, Steel, Critchlow-Fligner). A *P*-value <0.05 was considered statistically significant. No missing value imputation techniques were used.

RESULTS

The RE-BAV registry encompassed 814 patients with BAV, including 592 (72.7%) men. The mean (standard deviation [SD]) age was 50 (17.4) years. The most common symptoms reported were shortness of breath (54.1%) and chest pain (17.5%). The most common comorbid disease was hypertension (54.0%). 5.5% of patients had a history of cancer. Marfanoid features were present only in 9 (1.1%) participants. Clinical characteristics of the examined population is presented in Table 1.

Complex valvulo-aortopathy was present in 88 (10.8%) patients. The most common associated disorder was aortic coarctation found in 56 (7.1%) of the examined population. **Typical valvulo-aortopathy** with progressive BAV dysfunction and/or aortic dilatation without other major associated disorders was present in the majority of the examined population — 569 patients (69.9%), while **uncomplicated BAV** with mild or non-progressing valvulo-aortopathy without clinical manifestation was noted in 157 (19.3%).

Bicuspid aortic valve phenotypes

The BAV phenotype was identified in 640 patients (Table 1). The fusion type was most common (508 cases, 79.4%), followed by the double-sinus type (101 cases, 15.8%), and partial-cusp fusion (31 cases, 4.8%) ($P < 0.001$ for all comparisons) (Figure 3). Among the fusion phenotype, right-left fusion was most frequent (80.4%), followed by right-noncoronary (12.9%) and left-noncoronary cusp fusion (6.7%). Within the double-sinus type, the latero-lateral and antero-posterior phenotypes were equally common.

Differences between BAV phenotypes concerned patient age ($P < 0.001$), atrial fibrillation ($P < 0.001$), arterial hypertension ($P = 0.034$), nicotine addiction ($P = 0.019$), and NT-proBNP levels ($P = 0.021$). Patients with the 2-sinus type were the youngest, while those with the partial-fusion type were the oldest. Atrial fibrillation and arterial hypertension were most prevalent in the partial-fusion group, followed by the fused BAV and two-sinus types. Nicotine addiction was highest in the fused BAV group, while NT-proBNP levels were highest in the partial-fusion group. Cancer diagnoses were most common in the fused BAV type, although without significant differences between groups. Coronary artery disease was equally distributed among all BAV phenotypes.

Aortic dilatation was present in 302 (59.8%) patients with the fusion phenotype, 59 (58.4%) with two-sinus phenotype, and 17 (54.8%) with partial-fusion phenotype, with no significant differences. The type of aortic dilatation (ascending, root, or extended phenotype) did not vary among BAV phenotypes.

Echocardiographic examination

Transthoracic echocardiography was performed in all 814 subjects (Table 2). Additional imaging modalities were transesophageal echocardiography carried out in 19.3% and computed tomography in 22.5% of the population. The median duration of transthoracic echocardiography was 22 minutes (IQR 15–30). Slight hypertrophy of the left ventricular walls was observed, along with minor enlargement of the left atrium. Left ventricular ejection fraction was within normal limits, median (IQR): 60 (55–65)%. However global longitudinal strain was slightly depressed — mean (SD) -16.8% (3.7). Regional wall motion abnormalities were present in 11.9% of the population.

Significant (moderate/severe) aortic regurgitation was more common than stenosis (44.1% vs. 34.2%, respectively, McNemar's test $p < 0.001$). Significant mitral regurgitation was more common than tricuspid regurgitation (13.1% vs. 9.5%, respectively, McNemar's test $P = 0.003$). Data presented in Figure 4.

Aortic dilatation was observed in 513 patients (63.6%), with the most common type being the extended phenotype (root and ascending aorta) in 212 patients (26.3%), followed by the ascending aorta phenotype in 196 (24.3%) and root type in 105 (13.0%) ($P < 0.001$) (Table 2).

No aortic dissection was registered. After a heart-team decision, surgical intervention was scheduled in 139 patients (24.0%).

DISCUSSION

This registry offers a unique, large-scale overview of Polish patients with confirmed BAV, using the latest classification of BAV valvulo-aortopathy [2]. Improved noninvasive imaging, particularly echocardiography, has increased BAV diagnoses. Bicuspid aortic valve is a valvulo-aortopathy with diverse phenotypes, symptoms, and complications. Despite numerous studies, gaps remain in understanding BAV pathophysiology and clinical significance [8]. Most registries rely on small or retrospective samples with inconsistent classifications, complicating clinical practice, outcome prediction, and valve interventions [9–11].

This registry, based on voluntary participation of tertiary cardiac centers, ensured high data quality but does not allow estimation of the absolute prevalence of BAV in Poland. It focused on patients with heart defects or those qualified for intervention, leading to a relatively high average age, symptomatic cases in over half, and moderate-to-severe defects in over one-third. Bicuspid aortic valve patients are typically diagnosed and treated about a decade earlier than those with other aortic defect etiologies.

We analyzed BAV morphology and echocardiographic parameters in a large cohort of Polish adults from hospitals and outpatient clinics. Symptoms, comorbidities, valve dysfunction, aortic dilatation, and other pathologies were assessed. Valve phenotypes were classified using Michelena et al. criteria [2]. Transthoracic echocardiography was the primary imaging method, with transesophageal echocardiography or cardiac computed tomography performed in 20% of cases. All evaluations followed standardized protocols by expert echocardiographers.

Bicuspid aortic valve can be diagnosed at any age and in various clinical contexts. In our population (average age 50 years), BAV was more common in men (72.7%), consistent with previous data [12–14]. Similarly, in a younger cohort of 1135 children and adolescents, 67% of BAV cases were male [15].

Clinical presentations and comorbidities

Bicuspid aortic valve presentation can range from benign findings to severe complications like valve dysfunction, heart failure, or aortic aneurysm [8]. In our registry, the most common symptom was shortness of breath (54.1%), while 45.2% had no exercise limitations. Chest pain (17.5%) and syncope (5.6%) were also noted.

Comorbidities in BAV patients vary with age, often linked to genetic conditions in children and common diseases in adults. In our study, hypertension (54%), dyslipidemia (43.5%), coronary artery disease (16%), diabetes (10%), and atrial fibrillation (12.5%) were the most common, reflecting the cardiovascular risk profile of the studied Polish population. Other BAV registries report lower rates of hypertension (15%–38%), dyslipidemia (14%–30%), diabetes (6%–12%), and coronary artery disease (5%–14%) [13, 16–18].

Our registry uniquely categorizes BAV into three clinical-prognostic subgroups based on the latest expert consensus [2]. Most patients (69.9%) had typical valvulo-aortopathy with valve dysfunction and aortic dilatation, requiring long-term monitoring for risks like infective endocarditis, aortic dissection, and surgery. Uncomplicated BAV (present in 19.3%) is a mild, often incidental condition with non-progressing symptoms. Complex BAV with concomitant diseases, present only in 10.8%, included aortic coarctation as the most common associated pathology. This form of valvulo-aortopathy often requires surgical intervention at an earlier stage of life. Coexisting marfanoid features were rare (1.1%), consistent with previous reports [19].

Valvulopathy

Valvular dysfunction is common in BAV, with 33% developing significant aortic valve disease [20]. Bicuspid aortic valve is thought to have an autosomal dominant inheritance linked to defective heart development genes [21]. Dysfunction varies by fusion type, with regurgitation reported in 32%–43% and stenosis in 38%–62% in prior studies [13, 22]. In our cohort, regurgitation (44%) was more common than stenosis (34%), likely due to the high prevalence of right-left cusp fusion (80.4%), which predisposes to regurgitation. Right-noncoronary cusp fusion, less frequent in our cohort, is more prone to stenosis and surgery [22]. Ethnicity may also influence these patterns, as right-left cusp fusion is more common in Europeans than Asians (44.2% vs. 26.8%; $P < 0.001$) [17]. Understanding interethnic differences in BAV morphology and function is essential for optimizing global transcatheter aortic valve replacement strategies, as severe aortic stenosis remains the leading cause of aortic valve interventions [8, 23].

In our population, left and right ventricular dimensions were normal, but the left atrium was enlarged, and mild left ventricular hypertrophy was noted, consistent with other registries [13, 16, 18]. The peak aortic gradient was mildly elevated (21 mm Hg), and left ventricular ejection fraction was normal — mean (SD) 57.7% (10.3), which is in line with other studies [13, 18]. However, global longitudinal strain was slightly reduced — mean (SD) –16.8% (3.7), suggesting potential left ventricular overload due to altered BAV-related hemodynamics.

The study confirmed that fused-type anomalies are predominant, occurring in almost 80% of cases, though slightly lower than the 90%–95% reported in other studies, likely due to classification methods or ethnic differences [8]. Among fused BAV types, left-right coronary leaflet fusion was most common (80.4%), followed by right-noncoronary fusion, with left-noncoronary fusion being the least frequent (6.7%). The 2-sinus phenotype, present in 16% of cases, showed equal distribution of its subtypes (50% each). Patients with 2-sinus BAV type were younger and had fewer comorbidities, including lower rates of atrial fibrillation, nicotine addiction, and arterial hypertension. As noted in the Italian REBECCA registry, the 2-sinus form, though morphologically severe, is linked to fewer surgeries due to the younger population [13]. Its prevalence in our study aligns with French data [16] but is higher than in the International BAV Consortium study [8], likely reflecting ethnic and genetic diversity. Globally, the 2-sinus type is more common in Europeans, while the fusion type predominates in Asians [24]. The oldest age group was observed in fused BAV patients (average age 57), representing 4.8% of anomalies. This group had higher rates of comorbidities, including diabetes, hypertension, nicotine addiction, and the highest NT-proBNP levels, reflecting their age. Tachyarrhythmias, particularly atrial fibrillation, were more common in partial-fusion BAV, affecting 36.7% of patients. This rare subtype was identified more frequently in our registry due to advanced imaging techniques like high-resolution echocardiography and cardiac computed tomography. Previously, partial-fusion BAV was mainly recognized during valve or aortic surgeries [25–27].

Aortopathy

Bicuspid aortic valve aortopathy is common and heterogeneous, increasing the risk of aortic aneurysms and dissection. Altered hemodynamics and valve-related changes contribute to aortopathy, even in normally functioning valves, leading to asymmetric dilatation and wall stress, promoting aneurysm formation [28–30]. BAV aortopathy can occur independently of valvular dysfunction. The latest classification identifies three types of aortic dilatation [2], with

the frequency described at 70% for the ascending, 20% for the root, and 10% for the extended (10%) phenotype [31, 32].

In our cohort, aortic dilatation occurred in 64% of cases, with the extended phenotype being most frequent (26%), followed by the ascending (24%) and root (13%). In comparison, Kong et al. [17] in a study on almost 2 thousand patients reported aortic dilatation in 45% of cases, with the extended (14%) and root phenotypes (12%) predominating. Differences in prevalence likely stem from varying definitions. The root phenotype affects the root with mild ascending dilatation, while the ascending phenotype involves the ascending aorta with mild root dilatation. Our study measured absolute aortic dimensions using sex-specific cut-offs, without accounting for relative dilatation.

Limitations

Our registry, based on voluntary participation of tertiary cardiac centers, ensured high data quality but is not an epidemiological study and therefore provides no data on BAV prevalence in the Polish population. It lacks patient follow-up data, which is being collected for a future publication. Information on family history, pharmacotherapy, and outpatient versus hospitalized status was not included. While dyslipidemia data were provided, information on detailed lipid distribution, which could offer insights into its role in BAV-related calcific aortic stenosis, is lacking [33].

CONCLUSIONS

The first large-scale registry of BAV using the latest classification provides insights into the morphology of BAV-associated valvular and aortic phenotypes in the adult Polish population. The most common BAV phenotype was typical valvulo-artopathy, with the most frequent valvular and aortic malformation being the right-left fusion and extended aortic dilatation (root and ascending aorta), respectively. This spectrum is similar to the findings reported in other population and ethnicities, with only slight differences in the frequency of specific variants. Our study provides a basis for further research exploring the associations between BAV phenotypes and disease presentation.

Article information

Conflict of interest: None declared.

Funding: None.

Open access: This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, which allows downloading and sharing articles with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at polishheartjournal@ptkardio.pl

REFERENCES

1. Hoffman JIE, Kaplan S, Liberthson RR, et al. The incidence of congenital heart disease. *J Am Coll Cardiol.* 2002; 39(12): 1890–1900, doi: 10.1016/s0735-1097(02)01886-7, indexed in Pubmed: 12084585.
2. Michelena HI, Della Corte A, Evangelista A, et al. Summary: international consensus statement on nomenclature and classification of the congenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and research purposes. *Eur J Cardiothorac Surg.* 2021; 60(3): 481–496, doi: 10.1093/ejcts/ezab039, indexed in Pubmed: 34292332.
3. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* 2015; 28(1): 1–39.e14, doi: 10.1016/j.echo.2014.10.003, indexed in Pubmed: 25559473.
4. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J.* 2021; 43(7): 561–632, doi: 10.1093/eurheartj/ehab395, indexed in Pubmed: 34453165.
5. Evangelista A, Sitges M, Jondeau G, et al. Multimodality imaging in thoracic aortic diseases: A clinical consensus statement from the European Association of Cardiovascular Imaging and the European Society of Cardiology working group on aorta and peripheral vascular diseases. *Eur Heart J Cardiovasc Imaging.* 2023; 24(5): e65–e85, doi: 10.1093/ehjci/jead024, indexed in Pubmed: 36881779.
6. Isselbacher EM, Preventza O, Hamilton Black III J. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2022; 80(24): e223–e393, doi: 10.1016/j.jacc.2022.08.004, indexed in Pubmed: 36334952.

7. Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. *Eur Heart J*. 2024; 45(36): 3538–3700, doi: 10.1093/eurheartj/ehae179, indexed in Pubmed: 39210722.
8. Michelena HI, Prakash SK, Della Corte A, et al. Bicuspid aortic valve: identifying knowledge gaps and rising to the challenge from the International Bicuspid Aortic Valve Consortium (BAVCon). *Circulation*. 2014; 129(25): 2691–2704, doi: 10.1161/CIRCULATIONAHA.113.007851, indexed in Pubmed: 24958752.
9. Sievers HH, Schmidtke C. A classification system for the bicuspid aortic valve from 304 surgical specimens. *J Thorac Cardiovasc Surg*. 2007; 133(5): 1226–1233, doi: 10.1016/j.jtcvs.2007.01.039, indexed in Pubmed: 17467434.
10. Schaefer BM, Lewin MB, Stout KK, et al. The bicuspid aortic valve: an integrated phenotypic classification of leaflet morphology and aortic root shape. *Heart*. 2008; 94(12): 1634–1638, doi: 10.1136/hrt.2007.132092, indexed in Pubmed: 18308868.
11. Kang JW, Song HG, Yang DH, et al. Association between bicuspid aortic valve phenotype and patterns of valvular dysfunction and bicuspid aortopathy: comprehensive evaluation using MDCT and echocardiography. *JACC Cardiovasc Imaging*. 2013; 6(2): 150–161, doi: 10.1016/j.jcmg.2012.11.007, indexed in Pubmed: 23489528.
12. Sinning C, Zengin E, Kozlik-Feldmann R, et al. Bicuspid aortic valve and aortic coarctation in congenital heart disease-important aspects for treatment with focus on aortic vasculopathy. *Cardiovasc Diagn Ther*. 2018; 8(6): 780–788, doi: 10.21037/cdt.2018.09.20, indexed in Pubmed: 30740325.
13. Bellino M, Antonini-Canterin F, Bossone E, et al. Aortopathy and aortic valve surgery in patients with bicuspid aortic valve with and without raphe. *Int J Cardiol*. 2024; 407: 132000, doi: 10.1016/j.ijcard.2024.132000, indexed in Pubmed: 38561108.
14. Roman MJ, Pugh NL, Devereux RB, et al. Aortic dilatation associated with bicuspid aortic valve: relation to sex, hemodynamics, and valve morphology (the national heart lung and blood institute-sponsored national registry of genetically triggered thoracic aortic aneurysms and cardiovascular conditions). *Am J Cardiol*. 2017; 120(7): 1171–1175, doi: 10.1016/j.amjcard.2017.06.061, indexed in Pubmed: 28802510.
15. Fernandes SM, Sanders SP, Khairy P, et al. Morphology of bicuspid aortic valve in children and adolescents. *J Am Coll Cardiol*. 2004; 44(8): 1648–1651, doi: 10.1016/j.jacc.2004.05.063, indexed in Pubmed: 15489098.

16. Théron A, Touil A, Résseguier N, et al. Clinical insights into a tertiary care center cohort of patients with bicuspid aortic valve. *Int J Cardiovasc Imaging*. 2022; 38(1): 51–59, doi: 10.1007/s10554-021-02366-1, indexed in Pubmed: 34374902.
17. Kong WKF, Regeer MV, Ng ACT, et al. Sex differences in phenotypes of bicuspid aortic valve and aortopathy: Insights from a large multicenter, international registry. *Circ Cardiovasc Imaging*. 2017; 10(3): e005155, doi: 10.1161/CIRCIMAGING.116.005155, indexed in Pubmed: 28251911.
18. Hecht S, Butcher SC, Pio SM, et al. Impact of left ventricular ejection fraction on clinical outcomes in bicuspid aortic valve disease. *J Am Coll Cardiol*. 2022; 80(11): 1071–1084, doi: 10.1016/j.jacc.2022.06.032, indexed in Pubmed: 36075677.
19. Nistri S, Porciani MC, Attanasio M, et al. Association of Marfan syndrome and bicuspid aortic valve: Frequency and outcome. *Int J Cardiol*. 2012; 155(2): 324–325, doi: 10.1016/j.ijcard.2011.12.009, indexed in Pubmed: 22225761.
20. Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. *JAMA*. 2011; 306(10): 1104–1112, doi: 10.1001/jama.2011.1286, indexed in Pubmed: 21917581.
21. Prakash SK, Bossé Y, Muehlschlegel JD, et al. A roadmap to investigate the genetic basis of bicuspid aortic valve and its complications: Insights from the International BAVCon (Bicuspid Aortic Valve Consortium). *J Am Coll Cardiol*. 2014; 64(8): 832–839, doi: 10.1016/j.jacc.2014.04.073, indexed in Pubmed: 25145529.
22. Mai Z, Guan L, Mu Y. Association between bicuspid aortic valve phenotype and patterns of valvular dysfunction: A meta-analysis. *Clin Cardiol*. 2021; 44(12): 1683–1691, doi: 10.1002/clc.23736, indexed in Pubmed: 34734421.
23. Yang LT, Tribouilloy C, Masri A, et al. Clinical presentation and outcomes of adults with bicuspid aortic valves: 2020 update. *Prog Cardiovasc Dis*. 2020; 63(4): 434–441, doi: 10.1016/j.pcad.2020.05.010, indexed in Pubmed: 32485187.
24. Kong WKF, Regeer MV, Poh KK, et al. Inter-ethnic differences in valve morphology, valvular dysfunction, and aortopathy between Asian and European patients with bicuspid aortic valve. *Eur Heart J*. 2018; 39(15): 1308–1313, doi: 10.1093/eurheartj/ehx562, indexed in Pubmed: 29029058.
25. Sperling JS, Lubat E. Forme fruste or 'Incomplete' bicuspid aortic valves with very small raphe: The prevalence of bicuspid valve and its significance may be underestimated. *Int J Cardiol*. 2015; 184: 1–5, doi: 10.1016/j.ijcard.2015.02.013, indexed in Pubmed: 25705001.

26. Guala A, Rodriguez-Palomares J, Galian-Gay L, et al. Partial aortic valve leaflet fusion is related to deleterious alteration of proximal aorta hemodynamics. *Circulation*. 2019; 139(23): 2707–2709, doi: 10.1161/CIRCULATIONAHA.119.039693, indexed in Pubmed: 31158004.
27. Michelena HI, Yang LT, Enriquez-Sarano M, et al. The elusive 'forme fruste' bicuspid aortic valve: 3D transoesophageal echocardiography to the rescue. *Eur Heart J Cardiovasc Imaging*. 2020; 21(10): 1169, doi: 10.1093/ehjci/jeaa094, indexed in Pubmed: 32386424.
28. Lo Presti F, Guzzardi DG, Bancone C, et al. The science of BAV aortopathy. *Prog Cardiovasc Dis*. 2020; 63(4): 465–474, doi: 10.1016/j.pcad.2020.06.009, indexed in Pubmed: 32599028.
29. Fedak PWM, Barker AJ. Is concomitant aortopathy unique with bicuspid aortic valve stenosis? *J Am Coll Cardiol*. 2016; 67(15): 1797–1799, doi: 10.1016/j.jacc.2016.02.038, indexed in Pubmed: 27081019.
30. Johnson EMI, Scott MB, Jarvis K, et al. Global aortic pulse wave velocity is unchanged in bicuspid aortopathy with normal valve function but elevated in patients with aortic valve stenosis: Insights from a 4D flow MRI study of 597 subjects. *J Magn Reson Imaging*. 2023; 57(1): 126–136, doi: 10.1002/jmri.28266, indexed in Pubmed: 35633284.
31. Detaint D, Michelena HI, Nkomo VT, et al. Aortic dilatation patterns and rates in adults with bicuspid aortic valves: a comparative study with Marfan syndrome and degenerative aortopathy. *Heart*. 2014; 100(2): 126–134, doi: 10.1136/heartjnl-2013-304920, indexed in Pubmed: 24254191.
32. Della Corte A, Bancone C, Dialetto G, et al. The ascending aorta with bicuspid aortic valve: a phenotypic classification with potential prognostic significance. *Eur J Cardiothorac Surg*. 2014; 46(2): 240–247, doi: 10.1093/ejcts/ezt621, indexed in Pubmed: 24431175.
33. Waluś-Miarka M, Polus A, Idzior-Waluś B. Aortic valve and arterial calcification in patients with familial hypercholesterolemia. *Pol Heart J*. 2024; 82(2): 144–155, doi: 10.33963/v.phj.98945, indexed in Pubmed: 38348620.

Table 1. Clinical characteristics of patients with specific BAV phenotypes

Variable	n = 814	Fused BAV^a n = 508	2-sinus BAV^a n = 101	Partial-fusion BAV^a n = 31	P- overa ll test
Age, years, mean (SD)	50.0 (17.4)	53.0 (16.8)	46.3 (15.4)	57.2 (16.8)	<0.00 1¹
Male, n (%)	592 (72.7)	383 (75.5)	73 (72.3)	22 (71.0)	0.70
Weight, kg, mean (SD)	81.0 (16.7)	82.1 (16.5)	80.2 (17.0)	86.9 (21.4)	0.17
Height, cm, mean (SD)	173 (9.7)	174 (9.3)	173 (10.5)	173 (9.9)	0.83
BMI, kg/m ² , mean (SD)	26.8 (4.7)	27.0 (4.6)	26.5 (4.2)	28.9 (6.1)	0.06
Marfanoid features, n (%)	9 (1.1)	6 (1.2)	1 (1.0)	1 (3.4)	0.56
Heart rate, beats/min, median (IQR)	70 (65 – 77)	70 (64 – 78)	70 (65 - 77)	70 (65 – 85)	0.08
SBP, mm Hg, mean (SD)	128.0 (15.9)	129.5 (16,1)	126.8 (15,8)	124.2 (14,1)	0.09
DBP, mm Hg, mean (SD)	77.0 (11.0)	77.3 (10,7)	75.9 (13,5)	74.1 (11,7)	0.21
Symptoms					
Dyspnea at rest, n (%)	431 (54.1)	276 (55.5)	48 (48.0)	22 (71.0)	0.07
NYHA: III, IV, n (%)	68 (8.6)	53 (10.7)	5 (5.0)	5 (16.1)	0.12
Chest pain , n (%)	137 (17.5)	84 (17.4)	22 (22.4)	5 (16.7)	0.48
Syncope, n (%)	44 (5.6)	21 (4.3)	6 (6.1)	1 (3.3)	0.72
Concomitant diseases					
Coronary artery disease, n (%)	126 (16.0)	85 (17.4)	15 (15.6)	7 (22.6)	0.67
Myocardial infarction, n (%)	53 (6.7)	31 (6.3)	8 (8.2)	4 (12.9)	0.33
Stroke, n (%)	26 (3.4)	14 (2.9)	4 (4.3)	0 (0)	0.49

Ventricular arrhythmia, n (%)	60 (7.7)	39 (8.1)	3 (3.1)	4 (13.3)	0.11
Atrial fibrillation, n (%)	98 (12.5)	71 (14.7)	6 (6.2)	11 (36.7)	<0.001²
Other SVT, n (%)	85 (10.9)	50 (10.4)	12 (12.8)	7 (23.3)	0.09
Arterial hypertension, n (%)	422 (54.0)	281 (58.3)	43 (44.8)	20 (64.5)	0.034³
Dyslipidemia, n (%)	334 (43.5)	227 (48.1)	33 (35.5)	16 (53.3)	0.062
Diabetes, n (%)	80 (10.3)	58 (12.1)	5 (5.3)	6 (20.0)	0.051
Nicotine addiction, n (%)	157 (20.7)	124 (26.4)	13 (13.7)	5 (16.7)	0.019⁴
Neoplasm, n (%)	43 (5.5)	38 (7.9)	3 (3.1)	0 (0)	0.07
Active neoplasm, n (%)	15 (1.9)	12 (2.5)	2 (2.1)	0 (0)	0.67
NT-proBNP, pg/ml., median (IQR)	183 (58 – 871)	250 (73– 1151)	382 (169 - 1320)	1999 (435 – 4300)	0.021⁵
Clinical type of valvulo-aortopathy BAV disease					
Complex valvulo-aortopathy, n (%)	88 (10.8)	30 (5.9)	7 (6.9)	1 (3.2)	0.75
Typical valvulo-aortopathy, n (%)	569 (69.9)	381 (75.0)	68 (67.3)	23 (74.2)	0.28
Uncomplicated BAV, n (%)	157 (19.3)	97 (19.1)	26 (25.7)	7 (22.6)	0.30
Aortic coarctation, n (%)	56 (7.1)	13 (2.6)	4 (4.0)	0 (0)	0.48

Data presented as mean (standard deviation), median (interquartile range) or counts and percentage

^aGroup of 640 patients with specified BAV subtypes. ¹Fused BAV vs. 2-sinus BAV: $P < 0.001$, 2-sinus vs. partial fusion: $P = 0.004$. ²Fused BAV vs. 2-sinus BAV: $P = 0.02$, fused vs. partial fusion: $P = 0.004$, 2-sinus vs. partial fusion: $P < 0.001$. ³Fused BAV vs. 2-sinus BAV: $P = 0.015$, 2-sinus vs. partial fusion: $P = 0.056$. ⁴Fused BAV vs. 2-sinus BAV: $P = 0.01$. ⁵Fused BAV vs. partial fusion: $P = 0.023$, 2-sinus BAV vs. partial fusion: $P = 0.12$

Abbreviations: BAV, bicuspid aortic valve; BMI, body mass index; DBP, diastolic blood pressure; NTproBNP, N-terminal prohormone of brain natriuretic peptide; n, number of patients; NYHA, New York Heart Association; SBP, systolic blood pressure; SD, standard deviation; SVT, supraventricular tachycardia

Table 2. Echocardiographic data of the studied population (n = 814)

Variable	Statistics
Regional wall motion abnormalities, n (%)	96 (11.9)
LVESD, mm, mean (SD)	35.3 (8.6)
LVEDD, mm, mean (SD)	51.8 (8.3)
Interventricular septum, mm, mean (SD)	11.8 (2.5)
Posterior wall, mm, mean (SD)	10.7 (2.1)
Left atrium — AP dimension, mm, mean (SD)	38.5 (7.6)
Left atrial volume, ml/m ² , median (IQR)	39 (23.0–65.9)
Ejection fraction, 2D, %, median (IQR)	60 (55–65)
LVESV, ml, median (IQR)	60 (37–91)
LVEDV, ml, median (IQR)	126 (90–180)
GLS, %, mean (SD)	–16.8 (3.7)
LVOT, mm, mean (SD)	23.6 (3.4)
VTI LVOT, cm, mean (SD)	22.2 (7.4)
Tricuspid regurgitation V _{max} , m/s, mean (SD)	2.50 (0.55)
TAPSE, mm, mean (SD)	23.4 (4.3)
Aortic bulb, mm, mean (SD)	37.7 (5.9)
Sino-tubular junction, mm, mean (SD)	32.3 (5.8)
Ascending aorta, mm, mean (SD)	39.0 (7.5)
Aortic arch, mm, mean (SD)	28.8 (5.7)
Descending aorta, mm, mean (SD)	22.9 (4.2)
Aortic ring, mm, (SD)	25.2 (3.7)
Aortic dilatation, n (%)	513 (63.6)
Aortopathy form	
Ascending phenotype, n (%)	196 (24.3)
Root phenotype, n (%)	105 (13.0)
Extended phenotype, n (%)	212 (26.3)
Aortic valve V _{max} , m/s	2.6 (1.2)
Aortic valve Grad _{max} , mm Hg, median (IQR)	21 (11.6 – 50.0)
Aortic valve Grad _{mean} , mm Hg, median (IQR)	13.0 (6.5 - 34.0)



Aortic valve area, cm ² , median (IQR)	1.25 (0.9- 2.0)
CT — performance, n (%)	183 (22.5)
TEE — performance, n (%)	157 (19.3)
TTE examination time, min, median (IQR)	22 (15 – 30)
3D LVEF, n (%)	60 (7,37)

Data presented as mean (standard deviation), median (interquartile range) or counts and percentage

*Group of 640 patients with specified BAV subtypes

Abbreviations: AP, antero-posterior; CT, computed tomography; GLS, global longitudinal strain; Grad_{max}, maximal gradient; Grad_{mean}, mean gradient; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVOT, left ventricular outflow tract; n, number of patients; TAPSE, tricuspid annular plane systolic excursion; TEE, transoesophageal echocardiography; TTE, transthoracic echocardiography; V_{max} maximal velocity; VTI, velocity time integral; 3D, 3 dimensional echocardiography







C



D



E



F

Figure 1. Examples of bicuspid aortic valve (BAV) phenotypes. **A.** Fused BAV: right-left aortic cusp fusion in systole; TEE. **B.** Fused BAV: right-left aortic cusp fusion in diastole; TEE. **C.** Two-sinus BAV: antero-posterior type in systole; TEE. **D.** Two-sinus BAV: antero-posterior type in diastole; TEE. **E.** Partial-fusion BAV: partial left-noncoronary cusp fusion in systole; TTE. **F.** Partial-fusion BAV: partial left-noncoronary cusp fusion in diastole; TTE

Abbreviations: TEE, transoesophageal examination; TTE, transthoracic examination




Figure 2. Transthoracic 2-dimensional parasternal long axis view of the extended phenotype of aortic dilatation. Measurements of the left ventricular outflow tract (1), aortic root (2) and ascending aorta (3). The sino-tubular junction is undistinguishable in this case




Figure 3. Schematic representation of the frequency bicuspid aortic valve (BAV) types. The graph presents the relative frequency of each BAV type in relation to the 640 patients with specified BAV types




Figure 4. Schematic representation of the frequency and degree of valve diseases in the examined population. **A.** Aortic regurgitation. **B.** Aortic stenosis. **C.** Mitral regurgitation. **D.** Tricuspid regurgitation